p16(INK4A)-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases

Approximately 50% of patients with metastatic HER2-positive (HER2+) breast cancer develop brain metastases (BCBMs). We report that the tumor suppressor p16(INK4A) is deficient in the majority of HER2+ BCBMs. p16(INK4A)-deficiency as measured by protein immunohistochemistry predicted response to comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jing, Kabraji, Sheheryar, Xie, Shaozhen, Wang, Yanzhi, Pan, Peichen, He, Xiaofang, Liu, Zongming, Leone, Jose Palbo, Long, Henry W., Brown, Myles A., Winer, Eric P., Dillon, Deborah A. R., Lin, Nancy U., Zhao, Jean J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933392/
https://www.ncbi.nlm.nih.gov/pubmed/35304445
http://dx.doi.org/10.1038/s41467-022-29081-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933392/
https://www.ncbi.nlm.nih.gov/pubmed/35304445
http://dx.doi.org/10.1038/s41467-022-29081-2

Ejemplares similares